Keros Therapeutics Reports $229.4 Million Revenue for First Half of 2025, Plans $375 Million Capital Return

Keros Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated total revenue of $229.4 million for the first half of 2025, a substantial increase from just $120,000 in the same period of the previous year. This revenue surge was primarily driven by a $195.4 million license revenue from its agreement with Takeda Pharmaceuticals, which became effective in January 2025. In contrast, Keros reported a net loss of $30.7 million for the second quarter of 2025, an improvement from a loss of $45.3 million in the same quarter of 2024.

The company’s financial position has strengthened, with cash and cash equivalents rising to $690.2 million as of June 30, 2025, compared to $559.9 million at the end of 2024. This increase is attributed to the successful public offering in January 2024, which raised approximately $151.1 million, and the ongoing sales under its at-the-market (ATM) program. Keros also announced a plan to return $375 million in excess capital to stockholders, although the specifics of this return are still under consideration.

Operationally, Keros has made strategic decisions to streamline its workforce, reducing its employee count by approximately 45% as part of a restructuring plan aimed at achieving annualized cost savings of around $17 million. This restructuring is expected to be completed by the end of 2025. The company continues to focus on advancing its clinical programs, particularly KER-065 for Duchenne muscular dystrophy and elritercept for myelodysplastic syndromes, with plans to initiate a Phase 2 trial for KER-065 in early 2026.

Keros is navigating a competitive landscape in the biopharmaceutical industry, with several companies developing similar therapies. The company emphasizes the importance of its collaborations with Takeda and Hansoh for the commercialization of elritercept, as the success of these partnerships will significantly impact its revenue potential. Looking ahead, Keros anticipates continued operating losses as it invests heavily in research and development, but it remains optimistic about the long-term prospects of its product candidates and the potential for future revenue generation.